Today: 11 June 2026
UAMY Stock Skyrockets on $245M Pentagon Deal – Bubble or Buy?
11 November 2025
4 mins read

UAMY Stock Today (Nov. 11, 2025): United States Antimony Jumps on $106.7M Five‑Year Supply Deal as China Eases Antimony Export Ban; Q3 Results Due Tomorrow

Updated November 11, 2025

Key takeaways

  • New contract: United States Antimony Corporation (NYSE American: UAMY) executed a five‑year supply agreement valued at up to $106.7 million to deliver antimony trioxide to a U.S. industrial fabric manufacturer; the pact includes an option to extend up to five additional years. The customer was not named, and USAC says its material met the buyer’s technical specs in testing earlier this year. 
  • Price action: UAMY closed at $8.07 on Tuesday, up ~5% on the day. 
  • Macro backdrop: China suspended its ban on exports of gallium, germanium and antimony to the U.S. through Nov. 27, 2026, but licensing requirements remain—keeping some supply risk in the system. 
  • Earnings on deck: USAC will report Q3 2025 results Wednesday, Nov. 12 at 4:15 p.m. ET via webcast and call. Street previews vary, with revenue estimates near $12.9 million and EPS between $0.01 and $0.02

UAMY stock news today (Nov. 11, 2025)

US Antimony signs $106.7M, five‑year supply deal. Before the bell, USAC announced a definitive five‑year agreement to supply antimony trioxide—used primarily as a flame‑retardant synergist for industrial fabrics—to a U.S.‑based manufacturer. The company notes the customer completed materials testing earlier in 2025, and the contract includes a five‑year renewal option beyond the initial term. Headline value is “up to $106.7 million” across the first five years. ACCESS Newswire

Shares finished higher. On the news, UAMY settled at $8.07 (+~5%). While the close reflects upbeat sentiment around the fresh order book, traders will look for clarity on delivery timing, ramp cadence and any margin commentary on Wednesday’s call. 


Why this contract matters

The announcement is material for two reasons:

  1. Visibility and diversification. USAC’s book now spans civilian industrial demand (antimony trioxide for flame‑retardant applications) in addition to government demand for antimony metal. In September, the company disclosed a five‑year, sole‑source contract worth up to $245 million with the U.S. Defense Logistics Agency (DLA) to supply antimony ingots for the National Defense Stockpile. If both agreements are fulfilled at their maximum values, aggregate contracted opportunities exceed $351 million—a useful (if not guaranteed) directional indicator for potential revenue coverage over the next several years. 
  2. Domestic supply strategy. The buyer’s rationale, per the announcement, is to anchor critical inputs domesticallyand reduce exposure to international disruptions and price shocks. That theme is consistent with U.S. policy and private‑sector moves to localize critical‑mineral supply chains. 

Macro backdrop: China’s export stance shifts—but risk remains

The geopolitical overhang on antimony eased slightly after Beijing suspended its ban on shipments of gallium, germanium and antimony to the U.S., effective Nov. 9, 2025, as part of a broader de‑escalation package. Crucially, export licensing still applies, meaning administrative friction can continue to bottleneck flows and inject volatility into pricing. The suspension currently runs through Nov. 27, 2026

Market participants told Fastmarkets today that uncertainty still lingers: inspections, sporadic clearances and opaque policy signals keep buyers cautious even with the headline suspension. For domestic processors like USAC, that backdrop reinforces the value of home‑grown procurement and long‑term offtakes that reduce reliance on Chinese supply. 


Earnings preview: what to watch on Wednesday

US Antimony will release Q3 2025 financial and operating results on Wednesday, Nov. 12 at 4:15 p.m. ET, followed by a 60‑minute webcast and Q&A. The company has posted dial‑in details and a replay plan on its investor site and press‑release feed. 

  • Consensus snapshot: Previews vary across outlets: several trackers point to revenue around $12.86–$12.96 million and EPS between $0.01 and $0.02. Expect management’s guidance and color on the newly announced contract to drive the post‑call narrative. 

5 things investors should listen for:

  1. Revenue recognition timing for the new five‑year antimony trioxide agreement (start date, quarterly cadence, and any minimum volumes). 
  2. Margin profile of antimony trioxide relative to antimony metal and other product lines under current pricing. (Context: licensing remains in China, which can influence feedstock availability and premiums.) 
  3. DLA contract updates (delivery orders to date, logistics, and inventory readiness). 
  4. Feedstock strategy and procurement mix across the U.S., Mexico and Canada given lingering export‑license uncertainty. 
  5. Balance‑sheet capacity (working capital and capex needs) to support simultaneous government and commercial ramps.

Sector pulse: demand signals and competitive context

Antimony’s demand profile extends well beyond flame retardants. In an S&P Global Commodity Insights interview published today, Larvotto Resources’ MD highlighted growing antimony use in solar‑panel glass and optics, while also noting the U.S. supply gap that has drawn increased government and investor attention in 2025. The same piece references Larvotto’s Oct. 27 rejection of a takeover proposal from US Antimony, underscoring how strategic assets in the metal are being contested amid tight global supply. 


UAMY price and valuation snapshot (today)

  • Close: $8.07 (Tuesday, Nov. 11, 2025), roughly +5% on the day. 
  • Catalysts next 48 hours: Q3 print and guidance; any commentary on the $106.7M contract ramp and interplay with the $245M DLA award. 

Bottom line

For today, Nov. 11, 2025, the story around UAMY is straightforward: a new $106.7M five‑year commercial contractputs more visibility in the pipeline, the share price responded positively, and macro risk from China’s export regime is reduced but not removed. With earnings tomorrow, investors now shift from headlines to execution—seeking specifics on delivery timing, margin durability, and how management will sequence government and commercial demand through 2026. 


Disclosure: This article is for informational/educational purposes only and is not investment advice. Always do your own research.

Stock Market Today

  • Corn Prices Dip Ahead of USDA WASDE Report with Mixed Export Data
    June 11, 2026, 10:50 AM EDT. Corn futures fell by 2 to 3 ¼ cents Thursday ahead of the U.S. Department of Agriculture's (USDA) latest WASDE report, which is expected to show a 6 million bushel cut to old crop carryout and a 10 million bushel reduction in new crop stocks. July corn futures settled at $4.19 per bushel, down ½ cent. Export sales data indicated old crop sales between 0.7 and 1.6 million metric tons, while new crop sales ranged from 200,000 to 500,000 metric tons. Brazilian and Argentine corn production estimates increased slightly to 135.8 million and 60.8 million metric tons respectively. Ethanol production and stocks showed minor changes, with ethanol exports rising to 155,000 barrels per day. Traders remain cautious ahead of USDA's official projections on global corn supply.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
Sky on Fire Tonight: Giant ‘Solar Canyon’ Aims 800‑km/s Wind at Earth—Northern Lights Could Ignite 15 U.S. States & Test Global Tech
Previous Story

NOAA Issues G4 ‘Severe’ Geomagnetic Storm Watch for Nov. 12 After X5.1 Solar Flare — Northern Lights Possible as Far South as Indiana Tonight (Nov. 11)

iPhone Air Debuts, NASA Bars China & Mercedes’ 749‑Mile EV: Tech’s Hottest (Non‑AI) Headlines of Sept 12–13, 2025
Next Story

AI News Today (Nov 12, 2025): UK toughens child‑safety testing for AI, watchdog presses OpenAI on Sora, Foxconn teases OpenAI tie‑up, and legal‑tech funding tops $750M

Go toTop